BioInvent International AB (publ) (STO:BINV)
Sweden
· Delayed Price · Currency is SEK | Market Cap | 1.45B |
| Revenue (ttm) | 226.50M |
| Net Income (ttm) | -332.86M |
| Shares Out | 65.80M |
| EPS (ttm) | -5.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 95,812 |
| Average Volume | 94,635 |
| Open | 22.15 |
| Previous Close | 22.00 |
| Day's Range | 21.30 - 22.15 |
| 52-Week Range | 20.85 - 41.60 |
| Beta | -0.05 |
| RSI | 44.38 |
| Earnings Date | Mar 31, 2026 |
About STO:BINV
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company’s drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an anti-FcyRIIB antibody in Phase 1/2a trial for the treatment of non-Hodgkin’s lymphoma, as well as Phase 1/2a trial to treat advanced solid tumors; BI-19... [Read more]
Financial Performance
In 2025, STO:BINV's revenue was 226.50 million, an increase of 406.86% compared to the previous year's 44.69 million. Losses were -332.86 million, -22.48% less than in 2024.
Financial StatementsNews
BioInvent to Present Data of BI-1808 Plus KEYTRUDA(R) (Pembrolizumab) in Recurrent Ovarian Cancer at the 2026 ASCO Annual Meeting
BioInvent International (STO:BINV) - BI-1808 multiplies by three the overall response rate as compared to pembrolizumab alone, supporting its potential to enhance antitumoral immune responses when com...
BioInvent International AB Publishes Annual Report 2025
LUND, SE / ACCESS Newswire / March 31, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class i...
BioInvent Achieves Phase 3 Milestone for HMI-115 in Endometriosis
BioInvent International (STO:BINV) - Achievement of the milestone triggers a payment of € 1 million LUND, SE / ACCESS Newswire / March 26, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stock...
Notice to Annual General Meeting in BioInvent International AB
LUND, SE / ACCESS Newswire / March 24, 2026 / BioInvent International (STO:BINV) - The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual G...
BioInvent International AB (FRA:BIX0) Q4 2025 Earnings Call Highlights: Navigating Challenges ...
BioInvent International AB (FRA:BIX0) Q4 2025 Earnings Call Highlights: Navigating Challenges with Strategic Initiatives
Q4 2025 BioInvent International AB Earnings Call Transcript
Q4 2025 BioInvent International AB Earnings Call Transcript
BioInvent International AB Earnings Call Transcript: Q4 2025
Strong clinical progress in BI-1808 and BI-1206 programs, with robust efficacy and safety data in lymphoma and ovarian cancer. Financially, full-year net sales surged due to a major royalty deal, and liquidity supports operations for 12 months. Multiple pivotal trial milestones and partnering opportunities are expected in 2026–2027.
BioInvent International AB: Year-End Report January 1 - December 31, 2025
LUND, SE / ACCESS Newswire / February 26, 2026 / BioInvent International (STO:BINV) - "During 2025 we sharpened our clinical focus and resource allocation to accelerate our most advanced assets, BI-18...
BioInvent International AB Transcript: Jefferies London Healthcare Conference 2025
Two first-in-class immuno-oncology assets are advancing through phase 2 trials, showing strong efficacy and safety in both liquid and solid cancers. Strategic partnerships and a robust platform support rapid development, with pivotal studies and key data readouts planned through 2027.
BioInvent International AB (FRA:BIX0) Q3 2025 Earnings Call Highlights: Strategic Focus Amidst ...
BioInvent International AB (FRA:BIX0) Q3 2025 Earnings Call Highlights: Strategic Focus Amidst Financial Challenges
Q3 2025 BioInvent International AB Earnings Call Transcript
Q3 2025 BioInvent International AB Earnings Call Transcript
BioInvent International AB Earnings Call Transcript: Q3 2025
Lead programs BI-1808 and BI-1206 advanced to Phase II with strong early efficacy and safety data, driving portfolio reprioritization and accelerated clinical timelines. Financials show a significant increase in net sales due to a royalty rights deal, with liquidity secured into Q1 2027.
BioInvent International AB Transcript: Investing in Life Science 2025
The company is prioritizing its most advanced antibody programs, 1206 and 1808, with upcoming clinical data expected by year-end and H1 next year. Strategic partnerships, regulatory designations, and a strong financial position support a focused push toward solid cancer markets.
BioInvent International AB Transcript: Jefferies Global Healthcare Conference 2025
The conference highlighted a robust immuno-oncology pipeline with two lead assets, BL-1808 and BI-1206, both showing strong efficacy and safety in early clinical trials. Key milestones include pivotal phase 2 plans, regulatory designations, and multiple data readouts expected in 2024.
BioInvent International AB Transcript: Status Update
A SEK 30 million deal with Exoma Royalties provides funding for advancing a robust clinical pipeline, including promising phase 2a results for BI-1206 and BI-1808. Fast Track and orphan drug designations for BI-1808 accelerate development and market access.
BioInvent International AB Earnings Call Transcript: Q4 2024
Advanced clinical pipeline with BI-1808 and BI-1206 in phase II, strong early efficacy signals, and robust financial position with SEK 867 million in liquid funds. Key data readouts in 2025 are expected to drive partnering and financing opportunities.
BioInvent International AB Earnings Call Transcript: Q3 2024
Lead clinical programs reported strong efficacy and safety, with subQ formulations outperforming IV. Net sales and research funding declined year-over-year, but cash reserves remain robust. Multiple data readouts and potential strategic partnerships are expected in 2024–2025.
Transgene and BioInvent's Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments
Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatment In a patient with a heavily pretreated leiomyosarcoma, B...